Table 2.
Comparison between controls and ADPKD patients with stage 3 CKD
| Controls n = 498 (89.7%) |
ADPKD stage 3 CKD n = 57 (10.3%) |
p | |
|---|---|---|---|
| Age (years) | 53.69 ± 11.63 | 54.54 ± 11.73 | NS |
| Male gender | 262 (52.5%) | 30 (52.6%) | NS |
| Hypertension | 163 (32.7%) | 52 (91.2%) | < 0.001 |
| Dyslipidemia | 157 (31.5%) | 37 (64.9%) | < 0.001 |
| Creatinine (mg/dL) | 0.84 ± 0.15 | 1.69 ± 0.35 | < 0.001 |
| eGFR (mL/min/1.73m2) | 91.82 ± 16.94 | 41.13 ± 8.52 | < 0.001 |
| Macroalbuminuria | 0 (0.0%) | 5 (13.2%) | < 0.001 |
| Total cholesterol (mg/dL) | 204.41 ± 35.63 | 187.42 ± 40.68 | 0.001 |
| HDL-cholesterol (mg/dL) | 54.36 ± 15.38 | 49.05 ± 12.37 | 0.020 |
| LDL-cholesterol (mg/dL) | 128.73 ± 32.74 | 111.12 ± 31.93 | < 0.001 |
| Triglycerides (mg/dL) | 112.32 ± 66.08 | 132.82 ± 64.99 | 0.030 |
| Hemoglobin (g/dL) | 14.54 ± 1.41 | 13.56 ± 1.35 | < 0.001 |
| Albumin (g/dL) | 4.36 ± 0.30 | 4.23 ± 0.32 | 0.008 |
| Uric acid (mg/dL) | 5.05 ± 1.45 | 6.80 ± 1.28 | < 0.001 |
| iPTH (pg/mL) | 53.54 ± 15.34 | 96.79 ± 46.94 | < 0.001 |
| Potassium (mEq/L) | 4.47 ± 0.40 | 4.61 ± 0.45 | 0.017 |
| DBP (mmHg) | 79.84 ± 9.66 | 83.53 ± 9.35 | 0.006 |
| Overweight (BMI 25.1–30 Kg/m2) | 236 (47.3%) | 23 (46.9%) | < 0.001 |
| Target LDL-cholesterol | 349 (80.4%) | 23 (46.9%) | < 0.001 |
| Cardiovascular event | 11 (2.2%) | 0 (0.0%) | NS |
| Cardiovascular death | 0 (0.0%) | 0 (0.0%) | – |
| Non cardiovascular death | 3 (0.6%) | 1 (1.8%) | NS |
Abbreviations: ABI ankle brachial index, ADPKD autosomal dominant polycystic kidney disease, BMI body mass index, CKD chronic kidney disease, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate with the CKD-EPI formula, FGF-23 fibroblast growth factor 23, HDL high density lipoprotein, IMT intima-media thickness, iPTH intact parathyroid hormone, LDL low density lipoprotein, NS not statistically significant, SBP systolic blood pressure